Mir-210: A therapeutic target in cancer

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 1, 2013, Pages 21-28

  Hong, Liu ^a   Han, Yu ^a   Zhang, Hongwei ^a   Zhao, Qingchuan ^a   Qiao, Yuan ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; cell cycle; Human cancers; Hypoxia; MicroRNA; MiR 210; Survival

Indexed keywords

ANTAGOMIR; ANTINEOPLASTIC AGENT; CYTOCHROME C OXIDASE; CYTOKINE; EPHRIN A3; EPIGALLOCATECHIN GALLATE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE 1 LIKE; MEMBRANE PROTEIN; MICRORNA 210; PROTEIN ISCU; PROTEIN MNT; PROTEIN SHIP 1; SUCCINATE DEHYDROGENASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VACUOLE MEMBRANE PROTEIN 1;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE NECROSIS; BRAIN ISCHEMIA; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DNA REPAIR; DOWN REGULATION; DRUG TARGETING; HEART MUSCLE CELL; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84871255599     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.732066     Document Type: Review

References (60)

1. Li X, Wu K, Fan D. CIAPIN1 as a therapeutic target in cancer. Expert Opin Ther Targets 2010;14(6):603-10
2. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002;297(5589):2056-60
3. Hong L, Han Y, Li S, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10:1693-701
4. Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63
5. Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010;55:2545-51
6. Hong L, Li S, Han Y, et al. Angiogenesis-related molecular targets in esophageal cancer. Expert Opin Investig Drugs 2011;20:637-44
7. Crosby ME, Devlin CM, Glazer PM, et al. Emerging roles of microRNAs in the molecular responses to hypoxia. Curr Pharm Des 2009;15:3861-6
8. Gorospe M, Tominaga K, Wu X, et al. Post-transcriptional control of the hypoxic response by RNA-binding proteins and MicroRNAs. Front Mol Neurosci 2011;4:7
9. Devlin C, Greco S, Martelli F, Ivan M. miR-210: more than a silent player in hypoxia. IUBMB Life 2011;63(2):94-100
10. Huang X, Le QT, Giaccia AJ. MiR-210-micromanager of the hypoxia pathway. Trends Mol Med 2010;16(5):230-7
11. Wu WK, Law PT, Lee CW, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis2011;32(3):247-53
12. Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol 2011;3(2):140-55
13. McCormick R, Buffa FM, Ragoussis J, Harris AL. The role of hypoxia regulated microRNAs in cancer. Curr Top Microbiol Immunol 2010;345:47-70
14. Tsuchiya S, Fujiwara T, Sato F, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 2011;286(1):420-8
15. White NM, Bao TT, Grigull J, et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011;186(3):1077-83
16. Tan X, Qin W, Zhang L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011;17(21):6802-11
17. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011;11:374
18. Belian E, Kurucz R, Treue D, Lage H. Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. Anticancer Res 2010;30(2):629-33
19. Yabushita S, Fukamachi K, Tanaka H, et al. Circulating MicroRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas 2012; [Epub ahead of print]
20. Zeng L, Liu J, Wang Y, et al. MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011;3:1265-72
21. Toyama T, Kondo N, Endo Y, et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol 2012;42(4):256-63
22. Rothe F, Ignatiadis M, Chaboteaux C, et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011;6(6):e20980
23. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14(5):1340-8 (Pubitemid 351413913)
24. Volinia S, Galasso M, Sana ME, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 2012;109(8):3024-9
25. Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012;118(10):2603-14
26. Ren Y, Gao J, Liu JQ, et al. Differential signature of fecal microRNAs in patients with pancreatic cancer. Mol Med Rep 2012;6(1):201-9
27. Quero L, Dubois L, Lieuwes NG, et al. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol 2011;101(1):203-8
28. Gee HE, Camps C, Buffa FM, et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010;116(9):2148-58
29. Greither T, Wurl P, Grochola L, et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer 2012;130(5):1230-5
30. Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009;284(50):35134-43
31. Alaiti MA, Ishikawa M, Masuda H, et al. Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med 2012; [Epub ahead of print]
32. Chan SY, Loscalzo J. MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle 2010;9(6):1072-83
33. Faraonio R, Salerno P, Passaro F, et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ 2012;19(4):713-21
34. Yang W, Sun T, Cao J, et al. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res 2012;318(8):944-54
35. Nie Y, Han BM, Liu XB, et al. Identification of MicroRNAs involved in hypoxia- and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci 2011;7(6):762-8
36. Zhang GL, Li YX, Zheng SQ, et al. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010;88(2):169-75
37. Chen Z, Li Y, Zhang H, et al. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010;29(30):4362-8
38. Gambari R, Fabbri E, Borgatti M, et al. Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem Pharmacol 2011;82(10):1416-29
39. Wang H, Bian S, Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 2011;32(12):1881-9
40. Qin L, Chen Y, Niu Y, et al. A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway. BMC Genomics 2010;11:320
41. Manicardi A, Fabbri E, Tedeschi T, et al. Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells. ChemBioChem 2012;13(9):1327-37
42. Ota T, Doi K, Fujimoto T, et al. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 2012;32(6):2271-5
43. Chen WY, Liu WJ, Zhao YP, et al. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int 2012;11(3):319-24
44. Nakada C, Tsukamoto Y, Matsuura K, et al. Overexpression of miR-210, a downstream target of HIF1alpha, causes centrosome amplification in renal carcinoma cells. J Pathol 2011;224(2):280-8
45. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol 2011;301(4):H1519-30
46. Mizuno Y, Tokuzawa Y, Ninomiya Y, et al. miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett 2009;583(13):2263-8
47. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009;69(3):1221-9
48. Liu F, Lou YL, Wu J, et al. Upregulation of MicroRNA-210 regulates renal angiogenesis mediated by activation of VEGF signaling pathway under ischemia/perfusion injury in vivo and in vitro. Kidney Blood Press Res 2012;35(3):182-91
49. Qi J, Qiao Y, Wang P, et al. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett 2012;586(8):1201-7
50. Yamasaki K, Nakasa T, Miyaki S, et al. Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J Orthop Res 2012; [Epub ahead of print]
51. Kelly TJ, Souza AL, Clish CB, Puigserver P. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3- phosphate dehydrogenase 1-like. Mol Cell Biol 2011;31(13):2696-706
52. Lee DW, Futami M, Carroll M, et al. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene 2012; [Epub ahead of print]
53. Ying Q, Liang L, Guo W, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 2011;54(6):2064-75
54. Puissegur MP, Mazure NM, Bertero T, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2011;18(3):465-78
55. Zhang Z, Sun H, Dai H, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009;8(17):2756-68
56. Pulkkinen K, Malm T, Turunen M, et al. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 2008;582(16):2397-401
57. Favaro E, Ramachandran A, McCormick R, et al. MicroRNA-210 regulates mitochondrial free radical response to hypoxia and Krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. PLoS One 2010;5(4):e10345
58. Chan SY, Zhang YY, Hemann C, et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009;10(4):273-84
59. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283(23):15878-83
60. Ivan M, Harris AL, Martelli F, Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med 2008;12(5A):1426-31